[Research progress of double antithrombotic therapy in cardiovascular diseases]

K L Yan; X Y Zhao

doi:10.3760/cma.j.cn112148-20231019-00344

[Research progress of double antithrombotic therapy in cardiovascular diseases]

Zhonghua Xin Xue Guan Bing Za Zhi. 2023 Dec 24;51(12):1290-1294. doi: 10.3760/cma.j.cn112148-20231019-00344.

[Article in Chinese]

Authors

K L Yan¹, X Y Zhao¹

Affiliation

¹ Department of Cardiology, National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.

PMID: 38123215
DOI: 10.3760/cma.j.cn112148-20231019-00344

Abstract

在全球范围内，血栓所致心血管疾病仍存在较重疾病负担。长期以来抗血小板药物被认为是预防和治疗动脉血栓性疾病的基石，而抗凝药物被认为是静脉血栓性疾病的首选。近年来开展的一系列临床研究评估了双通道抑制，即联合抗血小板药物和抗凝药物的策略，在多种心血管疾病中的有效性和安全性，包括冠心病、缺血性卒中、外周血管疾病、深静脉血栓栓塞症、心房颤动、左心室血栓等，为改善心血管疾病患者的预后提供了新的治疗策略，并进一步降低了不良事件风险。该文总结了双通道抑制策略在心血管疾病中应用的最新临床证据。.

MeSH terms

Anticoagulants
Cardiovascular Diseases* / drug therapy
Fibrinolytic Agents / therapeutic use
Hemorrhage
Humans
Platelet Aggregation Inhibitors

Substances

Fibrinolytic Agents
Anticoagulants
Platelet Aggregation Inhibitors